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Abstract
Asymmetric bifunctional silyl ether (ABS) prodrugs of chemotherapeutics were synthesized and
incorporated within 200 nm x 200 nm particles. ABS prodrugs of gemcitabine were selected as
model compounds because of the difficulty to encapsulate a water soluble drug within a hydrogel.
The resulting drug delivery systems were degraded under acidic conditions and were found to
release only the parent or active drug. Furthermore, changing the steric bulk of the alkyl
substituents on the silicon atom could regulate the rate of drug release and therefore the
intracellular toxicity of the gemcitabine-loaded particles. This yielded a family of novel
nanoparticles that could be tuned to release drug over the course of hours, days, or months.
Introduction
Prodrugs are considered inactive molecules prior to administration but after exposure to
certain physiological conditions they are triggered to metabolize or spontaneously
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breakdown into an active therapeutic.1 Common physiological conditions used to degrade
prodrugs include acidic milieus, reducing environments and elevated enzymatic levels.2–4
Frequently, the acidic conditions known to exist in the endocytic pathway in cancer cells5 in
areas of inflammation6 and within tumor tissue7 are exploited to catalyze the degradation of
prodrugs. Consequently, a high payload of drug can be deposited in these areas thereby
increasing drug efficacy, reducing non-specific uptake by healthy tissue and increasing
patient compliance. Previously, acid sensitive prodrugs have been assembled using a number
of specialized chemistries including hydrazine,8 trityls,9 aconityls,10 vinyl ethers,11
poly(ketals),12,13 acetals,14 poly(ortho esters),15 and thiopropionates16 but these strategies
lack tunability, produce toxic byproducts, or necessitate exhaustive multi-step syntheses.
Silyl ethers are among the most widely used protecting groups for the alcohol functionally
because the rate of deprotection can be modulated by simply altering the substituents on the
silicon atom. As a result, the synthesis of small-molecule silyl ether prodrugs (Figure 1a)
have been explored using a variety of acid sensitive silane attachments including trimethyl
silyl ether (TMS), triethyl silyl ether (TES), and triisopropyl silyl ether (TIPS). Although
these materials are labile in vivo they are typically fastidious because of their vulnerability
to acidic workups.17 This limitation can be alleviated by incorporating silyl ether prodrugs
within a polymeric drug delivery system. The combination of a small molecule drug with
high molecular weight polymer provides protection for the therapeutic, and reduces the rate
of degradation. Previously, polybutadiene and polyamine polymers have been functionalized
with monofunctional silyl ether prodrugs (Figure 1b) of antiulcer prostaglandins,18,19 which
were designed to degrade under the harsh acidic environment found in the stomach.
Although these materials were acid sensitive and the therapeutic was released in a controlled
fashion the starting polymer and polymer by-product generated after degradation were not
water soluble, biodegradable or biocompatible. Furthermore, the reaction between the small
molecule drug and the chlorosilane decorated polymer gave incomplete conversion resulting
in low drug loading.
To mitigate these drawbacks, we have exploited the sensitivity and tunability of bifunctional
silyl ether linkers that are comprised of a C-O-Si-O-C bond arrangement (Figure 1c). The
implementation of an ether linkage on each side of the silicon atom allows for the acid
sensitive product to revert back to its original, unmodified starting material. This ensures
that the therapeutic will be released in its active form, and that the liberated biocompatible
polymer will be safe in the body after degradation. Previously, we employed bifunctional
silyl ether chemistry to fabricate microparticles that could be internalized within cells and
degrade under intracellular conditions. These microparticles showed little to no toxicity
because the silane byproducts were innocuous and the remaining polymer, poly(hydroxy
ethyl acrylate), was water soluble and biocompatible. Understanding the versatility of
bifunctional silyl ether chemistry, we set out to design a novel silyl ether prodrug that could
be incorporated within a nanoparticle carrier. Following exposure to the acid environment
found in cancer cells and tumors the nanoparticle would be triggered to release a high
payload of drug within the diseased site. Furthermore, changing the substituents on the
silicon atom would allow for controlled and tunable drug-release. The integration of silyl
ether prodrugs within nanoparticle would therefore provide a nano-device that could be
engineered to release a drug specifically at the site of disease and at a programmed rate
thereby minimizing toxic side effects.
Results and Discussion
Herein, and for the first time, we report how to incorporate a water soluble, clinically
relevant drug into a state-of-the-art nanoparticle platform using bifunctional silyl ether
chemistry. The bifunctional silyl ether functionality was selected as an ideal prodrug linkage
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for four reasons: 1) silyl ethers are typically acid sensitive and are known to degrade under
acidic conditions found in the body; 2) changing the substituents on the silicon atom allow
for the rate of drug release to be modulated or tuned; 3) non-toxic, commercially available
monomers or polymers are amenable with silyl ether chemistry and provide the necessary
functionality for the incorporation within nanoparticles and 4) upon degradation there is no
trace of the silyl ether modification on the drug. Furthermore, the synthesis requires only
one step and minimal work-up. For these reasons we believe that silyl ether prodrugs are far
superior to conventional prodrugs.
To show the versatility of silyl ether chemistry we selected three chemotherapeutics for their
pendant alcohol functionality. Specifically, camptothecin (CPT), dasatinib (DAS), and
gemcitabine (GEM) were identified as molecules that would be amenable with silyl ether
chemistry. Each prodrug was synthesized as a polymerizable monomer, which allowed for
facile incorporation and high drug loading within a nanoparticle. The modification occurred
by reacting a dichlorodialkyl silane (Et, iPr,) or di-t-butylsilyl ditriflate with the pendant
alcohol on the chemotherapeutic. Each conversion was monitored by thin layer
chromatography (TLC), and upon complete consumption of the starting material hydroxyl
ethyl acrylate (HEA) was added. The resulting molecule was synthesized in one step and
was composed of three parts; a chemotherapeutic, an acid sensitive bifunctional silyl ether
linkage, and a polymerizable monomer for particle fabrication (Figure 2).
We have elected to call this new class of prodrug an asymmetric bifunctional silyl ether
(ABS). From the three model chemo-therapeutics, gemcitabine was selected as an ideal
candidate for the incorporation within nanoparticles because of it is high water solubility and
hence its difficulty at being retained within a hydrogel particle for any significant period of
time. Typically, hydrophobic drugs are trapped within hydrophobic nanoparticles20 or
within hydrophobic cores of nanoparticles.21–23 Limited research has been conducted on
incorporating water soluble drugs within nanoparticles. This is likely due to the significant
loss of the cargo through diffusion or burst release once the particle is placed in an aqueous
environment. The incorporation of an ABS prodrug of gemcitabine within a nanoparticle
would therefore be useful and would confirm the versatility of the bifunctional silyl ether
linkage.
Three ABS prodrugs of gemcitabine, where the R groups were ethyl, isopropyl or tert-butyl,
were separately incorporated into “Trojan Horse” nanoparticles using a particle fabrication
technique called particle replication in nonwetting templates (PRINT).24 PRINT is a top-
down technique used to synthesize microparticles25,26 and nanoparticles27,28 with well-
defined shape and size. Cylindrical nanoparticles with dimensions of 200 nm x 200 nm were
fabricated (Figure 3) with 20 weight percent of the ABS prodrug, and the remaining bulk of
the particle was comprised of a crosslinker (PEG1000diacrylate), a positively charged agent
to facilitate cellular internalization (aminoethyl methacrylate-hydrochloride), a fluorescent
dye (fluorescein o-acrylate) and a photo-initiator (1-hydroxycyclohexyl phenyl ketone). This
particle composition was selected for its ability to rapidly internalize within acidic cellular
compartments. Detailed microscopy and internalization of this composition has been shown
elsewhere.27 Moreover, the degradation of this composition containing different bifunctional
silyl ether crosslinkers have been found to be non-toxic in multiple in vitro assays.29 For this
study, a high degree of crosslinking was implemented to facilitate slow and controlled
release of the gemcitabine cargo. Each particle fabricated with a gemcitabine ABS prodrug
had a particle size range of 299 ± 6.46 nm and a zeta potential of +22.5 ± 3.53 mV.
A quantitative analysis of gemcitabine release was performed on particles fabricated with
diethyl gemcitabine ABS prodrug (Et-GEM), diisopropyl gemcitabine ABS prodrug (iPr-
GEM) and di-tert-butyl gemcitabine ABS prodrug (tBu-GEM). The particles were degraded
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in solutions buffered at pH 5.0 and pH 7.4 to mimic intracellular and physiological
conditions respectively. The release experiment was maintained at 37°C and continued until
the particles no longer released gemcitabine. Aliquots of the solution were removed, filtered,
and the supernatant was analyzed by high performance liquid chromatography and
compared against the maximum theoretical loading to determine percent release and
encapsulation efficiency. Chromatograms taken at different time points over 1 day indicated
controlled release of gemcitabine from PRINT particles fabricated with the Et-GEM prodrug
(Figure 4). Moreover, the gemcitabine released from the PRINT particles had the same
retention time (~9.0 min) as the unmodified gemcitabine, demonstrating that only the active
form of the drug was being released from the particles.
A plot of gemcitabine release versus time for each particle can be seen in Figure 5. It was
apparent that as the steric bulk around the silicon atom increased the rate of drug release
decreased. For example, particles degraded at pH 5.0 had a half-life of release (t1/2) of 1.36
hours for Et-GEM, 68.5 hours for iPr-GEM, and 6995 hours for tBu-GEM (Table 1).
Particles degraded under physiological conditions (pH 7.4) showed a significantly slower
rate of release. Encapsulation efficiency of the gemcitabine within the nanoparticle was
determined by comparing the final concentration of released gemcitabine against the
theoretical loading of the ABS prodrug. For the particles fabricated with Et-GEM and iPr-
GEM the amount of gemcitabine released was > 95% of the theoretical maximum,
indicating near quantitative encapsulation of the drug within the nanoparticle.
To test the practicality of these nanoparticles under physiological conditions, cell viability
experiments were used to determine half maximal inhibitory concentrations (IC50) of each
gemcitabine ABS particle. This was accomplished by separately dosing a wide
concentration range of all three particle types (Et-GEM, iPr-GEM, and tBu-GEM) onto
LNCaP cells and comparing the cell viability against unmodified gemcitabine, and against
blank particles without drug. The cytotoxicity of each particle was determined using a
CellTiter-Glo luminescent cell viability assay after a 72 h incubation time (Figure 6).
Remarkably, the particles loaded with 20 weight percent of the tBu-GEM prodrug showed
the same cell viability as the blank particles, thereby completely halting the toxic nature of
the gemcitabine on LNCaP cells. This illustrates the high stability of the tert-butyl silyl ether
linkage and its ability to render the nanoparticle completely non-toxic even at extremely
high drug concentrations. The release of the drug from the nanoparticles could be modulated
by simply changing the steric bulk around the silyl ether leading to different effective
toxicities. Utilizing iPr-GEM and Et-GEM particles their respective IC50 values were
measured to be 2791 nM and 154 nM, with the latter being almost as toxic as the
unmodified gemcitabine. When compared to unmodified gemcitabine, particles fabricated
with Et-GEM, iPr-GEM and tBu-GEM prodrugs were 3.5, 64.3 and infinitely less toxic
respectively (Table 2). We attribute this decrease in toxicity to the time required for a
particle to internalize within a cell and the time required to degrade the silyl ether linkage
under intracellular conditions.
In order to visualize the effect of internalized ABS nanoparticles on cells, the particles were
dosed onto LNCaP cells and monitored using a PathScan apoptosis and proliferation
multiplex IF kit. This method allowed us to simultaneously monitor mitotic index and
programmed cell death using laser scanning confocal microscopy. The PathScan kit contains
a mixture of three primary antibodies targeted against α-tubulin, phosphor-histone H3
(Ser10), and cleaved –PARP (Asp214). The presence of α-tubulin (red in confocal)
indicates a healthy cell containing fundamental cytosolic fibers important in meiotic /
mitotic chromosome alignment. The presence of phosphor-histone H3 (green in confocal)
also indicates a healthy cell undergoing microtubule assembly during mitosis. Finally,
cleaved –PARP (nucleus appears purple in confocal) is indicative of cytoskeleton proteins
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and nuclear protein experiencing an apoptotic event. Due to the high toxicity of gemcitabine
on LNCaP cells it was extremely difficult to find and image cells dosed with free
gemcitabine or dosed with Et-GEM particles. The small number of remaining cells showed a
deep purple nucleus and limited α-tubulin indicating the onset of apoptosis. Conversely,
cells dosed with blank particles or with tBu-GEM particles showed healthy α-tubulin fibers
and in both cases mitotic events were clearly visible in green. This further confirms the
similar toxicity of Et-GEM particles to free gemcitabine. Moreover, this experiment
validates the tunability of a silyl ether linkage from highly labile and toxic Et-GEM ABS to
exceedingly stabile and non-toxic tBu-GEM ABS.
Conclusion
Asymmetric bifunctional silyl ether prodrugs were synthesized and analyzed as potential
materials for controlled drug delivery in nanoparticles. Using one simple step we were able
to synthesize a host of potential prodrugs from camptothecin, dasatinib, and gemcitabine.
The ABS prodrugs of gemcitabine were incorporated into 200 nm x 200 nm PRINT
nanoparticles and showed controlled and tunable release of gemcitabine. The rate of release
increased as the steric bulk of the substituent on the silicon atom decreased. HPLC analysis
confirmed that subsequent to silyl ether degradation the prodrug reverted back to the original
active form without any residual modification. Furthermore, release of the drug was
accelerated by exposure to acidic conditions similar to those found in the cellular endocytic
cycle. Detailed cellular in vitro experiments demonstrated that a particle could be fabricated
to release drug rapidly and with comparable toxicities to the free drug. Particles could also
be fabricated to release drug remarkably slow with minimal toxicity regardless of drug
loading. Additional exploration into ABS prodrugs could lead to the development of
nanoparticles with the ability to of release drugs specifically at the diseased site in a
controlled fashion. This type of treatment would be capable of treating a real world problem
like cancer, while simultaneously reducing the side effects associtiated with conventional
therapy.
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Three types of silyl ether prodrugs a) small molecule monofunctional silyl ether, b)
polymeric monofunctional silyl ether prodrug, and c) polymeric asymmetric bifunctional
silyl ether prodrug.
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Asymmetric bifunctional silyl ether (ABS) prodrugs of camptothecin, dasatinib, and
gemcitabine. Each ABS prodrug is comprised of three parts 1) a chemotherapeutic (green),
2) a silyl ether linkage (red), and 3) a polymerizable monomer for particle incorporation
(blue).
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Scanning electron micrograph of 200 nm x 200 nm PRINT particles containing gemcitabine
(scale bar = 1 μm).
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Chromatograms of the unmodified gemcitabine (black) and gemcitabine released from
nanoparticles fabricated with diethyl gemcitabine ABS prodrug over 24 hours.
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Percent release of gemcitabine versus time for 200 nm x 200 nm PRINT nanoparticles
fabricated with Et-GEM (Blue), iPr-GEM (red), and tBu-GEM (green) pro-drugs. Closed
symbols represent particles degraded at pH 5.0 and open symbols represent particles
degraded at pH 7.4.
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Cell viability assay (CellTiter-Glo) of 200 nm x 200 nm particles fabricated from Et-GEM
(Blue), iPr-GEM (red), and tBu-GEM (green) prodrugs versus blank particles (purple) and
free gemcitabine (black). The assay was performed using LnCAP cells.
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Confocal microscopy images of LNCaP cells stained with PathScan apoptosis and
proliferation kit. The cell were separately dosed with a) free gemcitabine, b) Et-GEM
particles, c) tBu-GEM particles, and d) blank particles. Red indicates a healthy cell
containing fundamental cytosolic fibers important in meiotic / mitotic chromosome
alignment. Green indicates a healthy cell undergoing microtubule assembly during mitosis.
Purple indicates cytoskeleton proteins and nuclear protein experiencing an apoptotic event.
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